In a clinical trial of anti-BCMA autologous CAR T cell treatment for multiple myeloma, the infused CD4:CD8 T cell ratio and frequency of CD45RO-CD27+CD8+ T cells correlated with CAR T expansion as well as clinical responses (68). Here, CD8A is linked to plasma cell myeloma.